Communiqués de presse Archive - Page 23 of 24 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Receives Special Recognition for European Growth

OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting

OSE Immunotherapeutics will participate in HealthTech Investor Days

Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient

OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Use of Tedopi® to Treat Brain Metastasis

OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum

OSE Immunotherapeutics to Host Key Opinion Leader Meeting

OSE Immunotherapeutics Receives Notice of Allowance for New U.S. Patent Protecting OSE-127

OSE Immunotherapeutics Announces Publication on OSE-127

Précédent
1
…
20
21
22
23
24
Suivant